329 related articles for article (PubMed ID: 29602853)
1. Association between refill adherence to lipid-lowering medications and the risk of cardiovascular disease and mortality in Swedish patients with type 2 diabetes mellitus: a nationwide cohort study.
Karlsson SA; Hero C; Svensson AM; Franzén S; Miftaraj M; Gudbjörnsdottir S; Eeg-Olofsson K; Eliasson B; Andersson Sundell K
BMJ Open; 2018 Mar; 8(3):e020309. PubMed ID: 29602853
[TBL] [Abstract][Full Text] [Related]
2. Risk of cardiovascular event and mortality in relation to refill and guideline adherence to lipid-lowering medications among patients with type 2 diabetes mellitus in Sweden.
Karlsson SA; Eliasson B; Franzén S; Miftaraj M; Svensson AM; Andersson Sundell K
BMJ Open Diabetes Res Care; 2019; 7(1):e000639. PubMed ID: 31114701
[TBL] [Abstract][Full Text] [Related]
3. Refill adherence and persistence to lipid-lowering medicines in patients with type 2 diabetes: A nation-wide register-based study.
Karlsson SA; Hero C; Eliasson B; Franzén S; Svensson AM; Miftaraj M; Gudbjörnsdottir S; Eeg-Olofsson K; Andersson Sundell K
Pharmacoepidemiol Drug Saf; 2017 Oct; 26(10):1220-1232. PubMed ID: 28799214
[TBL] [Abstract][Full Text] [Related]
4. Adherence to lipid-lowering therapy and risk for cardiovascular disease and death in type 1 diabetes mellitus: a population-based study from the Swedish National Diabetes Register.
Hero C; Karlsson SA; Franzén S; Svensson AM; Miftaraj M; Gudbjörnsdottir S; Andersson Sundell K; Eliasson B; Eeg-Olofsson K
BMJ Open Diabetes Res Care; 2020 Jan; 8(1):. PubMed ID: 31958300
[TBL] [Abstract][Full Text] [Related]
5. Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register.
Karlsson SA; Franzén S; Svensson AM; Miftaraj M; Eliasson B; Andersson Sundell K
BMC Health Serv Res; 2018 Nov; 18(1):900. PubMed ID: 30486824
[TBL] [Abstract][Full Text] [Related]
6. Initiation and maintenance of cardiovascular medications following cardiovascular risk assessment in a large primary care cohort: PREDICT CVD-16.
Mehta S; Wells S; Grey C; Riddell T; Kerr A; Marshall R; Ameratunga S; Harrison J; Kenealy T; Bramley D; Chan WC; Thornley S; Sundborn G; Jackson R
Eur J Prev Cardiol; 2014 Feb; 21(2):192-202. PubMed ID: 23033546
[TBL] [Abstract][Full Text] [Related]
7. Post-myocardial Infarction (MI) Care: Medication Adherence for Secondary Prevention After MI in a Large Real-world Population.
Huber CA; Meyer MR; Steffel J; Blozik E; Reich O; Rosemann T
Clin Ther; 2019 Jan; 41(1):107-117. PubMed ID: 30591287
[TBL] [Abstract][Full Text] [Related]
8. Validity of the adherence estimator in the prediction of 9-month persistence with medications prescribed for chronic diseases: a prospective analysis of data from pharmacy claims.
McHorney CA; Victor Spain C; Alexander CM; Simmons J
Clin Ther; 2009 Nov; 31(11):2584-607. PubMed ID: 20110004
[TBL] [Abstract][Full Text] [Related]
9. Adherence and persistence to urate-lowering therapies in the Irish setting.
McGowan B; Bennett K; Silke C; Whelan B
Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
[TBL] [Abstract][Full Text] [Related]
10. LDL cholesterol is not a good marker of cardiovascular risk in Type 1 diabetes.
Hero C; Svensson AM; Gidlund P; Gudbjörnsdottir S; Eliasson B; Eeg-Olofsson K
Diabet Med; 2016 Mar; 33(3):316-23. PubMed ID: 26498834
[TBL] [Abstract][Full Text] [Related]
11. Impact of Socioeconomic Factors and Gender on Refill Adherence and Persistence to Lipid-Lowering Therapy in Type 1 Diabetes.
Hero C; Karlsson SA; Franzén S; Svensson AM; Miftaraj M; Gudbjörnsdottír S; Andersson-Sundell K; Eliasson B; Eeg-Olofsson K
Diabetes Ther; 2021 Sep; 12(9):2371-2386. PubMed ID: 34292559
[TBL] [Abstract][Full Text] [Related]
12. MAP study: RCT of a medication adherence program for patients with type 2 diabetes.
Odegard PS; Christensen DB
J Am Pharm Assoc (2003); 2012; 52(6):753-62. PubMed ID: 23229961
[TBL] [Abstract][Full Text] [Related]
13. [Adherence to antihypertensive and lipid-lowering medications: a problem of public health, not yet resolved].
Grosso G; Raciti T; Marventano S; Romeo I; Mistretta A
Ann Ig; 2011; 23(2):173-84. PubMed ID: 21770233
[TBL] [Abstract][Full Text] [Related]
14. Association Between Use of Lipid-Lowering Therapy and Cardiovascular Diseases and Death in Individuals With Type 1 Diabetes.
Hero C; Rawshani A; Svensson AM; Franzén S; Eliasson B; Eeg-Olofsson K; Gudbjörnsdottir S
Diabetes Care; 2016 Jun; 39(6):996-1003. PubMed ID: 27208327
[TBL] [Abstract][Full Text] [Related]
15. Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus.
Berkelmans GFN; Gudbjörnsdottir S; Visseren FLJ; Wild SH; Franzen S; Chalmers J; Davis BR; Poulter NR; Spijkerman AM; Woodward M; Pressel SL; Gupta AK; van der Schouw YT; Svensson AM; van der Graaf Y; Read SH; Eliasson B; Dorresteijn JAN
Eur Heart J; 2019 Sep; 40(34):2899-2906. PubMed ID: 30629157
[TBL] [Abstract][Full Text] [Related]
16. Differences in cardiovascular disease risk when antihypertensive medication adherence is assessed by pharmacy fill versus self-report: the Cohort Study of Medication Adherence among Older Adults (CoSMO).
Krousel-Wood M; Holt E; Joyce C; Ruiz R; Dornelles A; Webber LS; Morisky DE; Frohlich ED; Re RN; He J; Whelton PK; Muntner P
J Hypertens; 2015 Feb; 33(2):412-20. PubMed ID: 25304468
[TBL] [Abstract][Full Text] [Related]
17. Characteristics Relating to Adherence and Persistence to Basal Insulin Regimens Among Elderly Insulin-Naïve Patients with Type 2 Diabetes: Pre-Filled Pens versus Vials/Syringes.
Slabaugh SL; Bouchard JR; Li Y; Baltz JC; Meah YA; Moretz DC
Adv Ther; 2015 Dec; 32(12):1206-21. PubMed ID: 26563324
[TBL] [Abstract][Full Text] [Related]
18. Blood pressure and complications in individuals with type 2 diabetes and no previous cardiovascular disease: national population based cohort study.
Adamsson Eryd S; Gudbjörnsdottir S; Manhem K; Rosengren A; Svensson AM; Miftaraj M; Franzén S; Björck S
BMJ; 2016 Aug; 354():i4070. PubMed ID: 27492939
[TBL] [Abstract][Full Text] [Related]
19. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people.
Schramm TK; Gislason GH; Køber L; Rasmussen S; Rasmussen JN; Abildstrøm SZ; Hansen ML; Folke F; Buch P; Madsen M; Vaag A; Torp-Pedersen C
Circulation; 2008 Apr; 117(15):1945-54. PubMed ID: 18378618
[TBL] [Abstract][Full Text] [Related]
20. Treatment adherence in newly diagnosed type 2 diabetes: patient characteristics and long-term impact of adherence on inpatient care utilization.
Sun P; Lian J
Postgrad Med; 2016 May; 128(4):338-45. PubMed ID: 26849064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
